Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-04

AUTHORS

Satoshi Yuuki, Yoshito Komatsu, Nozomu Fuse, Takashi Kato, Takuto Miyagishima, Mineo Kudo, Masao Watanabe, Miki Tateyama, Yasuyuki Kunieda, Osamu Wakahama, Yu Sakata, Masahiro Asaka

ABSTRACT

Background: Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial.Objective: To (i) identify the optimal regimen for IFL therapy in terms of irinotecan dosage, and (ii) determine the maximum tolerated dose and efficacy of the modified-IFL regimen in patients with histologically confirmed advanced colorectal cancer.Methods: In a phase I study, nine patients with advanced colorectal cancer received IFL treatment modified such that irinotecan was administered every 2 weeks, as opposed to the more toxic once-weekly administration. The study evaluated three escalating dose levels of irinotecan (100,125 and 150 mg/m2). Each treatment cycle consisted of irinotecan on days 1 and 15; fluorouracil 600 mg/m2 on days 1,8, 15 and 22; and levoleucovorin 250 mg/m2 on days 1, 8, 15 and 22. Data from the phase I study were used to determine the recommended dose of irinotecan for the phase II study. The latter study evaluated the effectiveness (overall response rate, median time to disease progression and median survival time) and tolerability of this modified-IFL therapy as ambulatory treatment in 22 patients with advanced colorectal cancer.Results: The dose-limiting toxicity of irinotecan was grade 3 neutropenia, which occurred in three patients at dose level 2 (125 mg/m2); furthermore, a fourth patient developed grade 4 neutropenia at this dose level. Therefore, 125 mg/m2 was considered to be the maximum tolerated dose, and the dose of irinotecan for the phase II study was set at 100 mg/m2. Fourteen patients achieved partial response using this modified-IFL regimen, and the overall response rate was 63.6% (95% CI 43.5, 83.7). The median time to progression was 197 days (range 111–283 days) and the median survival time was 414 days (95% CI 116, 712). Toxicities were acceptable and manageable.Conclusions: Modified-IFL therapy is a practical, effective and tolerable option for ambulatory treatment of advanced colorectal cancer. More... »

PAGES

243-249

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/11534470-000000000-00000

DOI

http://dx.doi.org/10.2165/11534470-000000000-00000

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048774064

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20225907


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ambulatory Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leucovorin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Hokkaido University, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.39158.36", 
          "name": [
            "Department of Gastroenterology, Hokkaido University, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuuki", 
        "givenName": "Satoshi", 
        "id": "sg:person.01353257533.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353257533.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cancer Chemotherapy Division, Hokkaido University Hospital Cancer Center, Nishi-5, Kita-14, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412167.7", 
          "name": [
            "Department of Cancer Chemotherapy Division, Hokkaido University Hospital Cancer Center, Nishi-5, Kita-14, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komatsu", 
        "givenName": "Yoshito", 
        "id": "sg:person.01360270073.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360270073.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Hokkaido University, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.39158.36", 
          "name": [
            "Department of Gastroenterology, Hokkaido University, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fuse", 
        "givenName": "Nozomu", 
        "id": "sg:person.01157021235.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157021235.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Hokkaido University, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.39158.36", 
          "name": [
            "Department of Gastroenterology, Hokkaido University, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kato", 
        "givenName": "Takashi", 
        "id": "sg:person.015540620202.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015540620202.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Hokkaido University, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.39158.36", 
          "name": [
            "Department of Gastroenterology, Hokkaido University, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyagishima", 
        "givenName": "Takuto", 
        "id": "sg:person.01012215233.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012215233.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Hokkaido University, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.39158.36", 
          "name": [
            "Department of Gastroenterology, Hokkaido University, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kudo", 
        "givenName": "Mineo", 
        "id": "sg:person.01226775545.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226775545.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Hokkaido University, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.39158.36", 
          "name": [
            "Department of Gastroenterology, Hokkaido University, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watanabe", 
        "givenName": "Masao", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Hokkaido University, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.39158.36", 
          "name": [
            "Department of Gastroenterology, Hokkaido University, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tateyama", 
        "givenName": "Miki", 
        "id": "sg:person.01112102072.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112102072.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Hokkaido University, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.39158.36", 
          "name": [
            "Department of Gastroenterology, Hokkaido University, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kunieda", 
        "givenName": "Yasuyuki", 
        "id": "sg:person.01253074264.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253074264.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Hokkaido University, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.39158.36", 
          "name": [
            "Department of Gastroenterology, Hokkaido University, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wakahama", 
        "givenName": "Osamu", 
        "id": "sg:person.01136563775.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136563775.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Misawa City Hospital, Misawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.459767.e", 
          "name": [
            "Department of Gastroenterology, Misawa City Hospital, Misawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakata", 
        "givenName": "Yu", 
        "id": "sg:person.011653372052.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011653372052.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Hokkaido University, Sapporo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.39158.36", 
          "name": [
            "Department of Gastroenterology, Hokkaido University, Sapporo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Asaka", 
        "givenName": "Masahiro", 
        "id": "sg:person.0713475270.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713475270.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10147-004-0407-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037532393", 
          "https://doi.org/10.1007/s10147-004-0407-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-003-0585-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075267208", 
          "https://doi.org/10.1007/s00280-003-0585-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-04", 
    "datePublishedReg": "2010-04-01", 
    "description": "Background: Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial.Objective: To (i) identify the optimal regimen for IFL therapy in terms of irinotecan dosage, and (ii) determine the maximum tolerated dose and efficacy of the modified-IFL regimen in patients with histologically confirmed advanced colorectal cancer.Methods: In a phase I study, nine patients with advanced colorectal cancer received IFL treatment modified such that irinotecan was administered every 2 weeks, as opposed to the more toxic once-weekly administration. The study evaluated three escalating dose levels of irinotecan (100,125 and 150 mg/m2). Each treatment cycle consisted of irinotecan on days 1 and 15; fluorouracil 600 mg/m2 on days 1,8, 15 and 22; and levoleucovorin 250 mg/m2 on days 1, 8, 15 and 22. Data from the phase I study were used to determine the recommended dose of irinotecan for the phase II study. The latter study evaluated the effectiveness (overall response rate, median time to disease progression and median survival time) and tolerability of this modified-IFL therapy as ambulatory treatment in 22 patients with advanced colorectal cancer.Results: The dose-limiting toxicity of irinotecan was grade 3 neutropenia, which occurred in three patients at dose level 2 (125 mg/m2); furthermore, a fourth patient developed grade 4 neutropenia at this dose level. Therefore, 125 mg/m2 was considered to be the maximum tolerated dose, and the dose of irinotecan for the phase II study was set at 100 mg/m2. Fourteen patients achieved partial response using this modified-IFL regimen, and the overall response rate was 63.6% (95% CI 43.5, 83.7). The median time to progression was 197 days (range 111\u2013283 days) and the median survival time was 414 days (95% CI 116, 712). Toxicities were acceptable and manageable.Conclusions: Modified-IFL therapy is a practical, effective and tolerable option for ambulatory treatment of advanced colorectal cancer.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/11534470-000000000-00000", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "30"
      }
    ], 
    "keywords": [
      "advanced colorectal cancer", 
      "metastatic colorectal cancer", 
      "dose of irinotecan", 
      "phase II study", 
      "colorectal cancer", 
      "ambulatory treatment", 
      "IFL therapy", 
      "IFL regimen", 
      "II study", 
      "dose levels", 
      "day 1", 
      "phase I", 
      "grade 3 neutropenia", 
      "dose level 2", 
      "grade 4 neutropenia", 
      "dose-limiting toxicity", 
      "median survival time", 
      "overall response rate", 
      "irinotecan dosage", 
      "IFL treatment", 
      "tolerable option", 
      "standard regimen", 
      "optimal regimen", 
      "weekly administration", 
      "partial response", 
      "fourth patient", 
      "median time", 
      "combined therapy", 
      "survival time", 
      "patients", 
      "irinotecan", 
      "regimen", 
      "treatment cycles", 
      "response rate", 
      "therapy", 
      "cancer", 
      "dose", 
      "neutropenia", 
      "treatment", 
      "toxicity", 
      "days", 
      "levoleucovorin", 
      "latter study", 
      "tolerability", 
      "level 2", 
      "fluorouracil", 
      "study", 
      "administration", 
      "progression", 
      "weeks", 
      "efficacy", 
      "m2", 
      "levels", 
      "dosage", 
      "options", 
      "response", 
      "effectiveness", 
      "rate", 
      "time", 
      "data", 
      "cycle", 
      "maximum", 
      "position", 
      "terms"
    ], 
    "name": "Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer", 
    "pagination": "243-249", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048774064"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/11534470-000000000-00000"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20225907"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/11534470-000000000-00000", 
      "https://app.dimensions.ai/details/publication/pub.1048774064"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_517.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/11534470-000000000-00000"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/11534470-000000000-00000'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/11534470-000000000-00000'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/11534470-000000000-00000'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/11534470-000000000-00000'


 

This table displays all metadata directly associated to this object as RDF triples.

299 TRIPLES      21 PREDICATES      113 URIs      103 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/11534470-000000000-00000 schema:about N0b08eb48509a4d89a0a3f9fa65a391f3
2 N15af61532dd34f4398509678bdb36ed4
3 N1fff0c0f40a341bd9fee9206e14b73fa
4 N22ae5899f740418d8a1176729a393cf9
5 N378e8f7a732543e3a25e040d34b4d888
6 N46c7216e5eb349f4bacd75317ec6ea8b
7 N5a69455595dc46e385410333b5deb080
8 N620ae9c4978542e8b03ac960bb2bbc96
9 N644a6aafdb6c4fc49790c3b18791a9f9
10 N72d960427b44453c8a2d06d956365a81
11 N76626651d94643b1bc61db4415f1d909
12 N76e0d04a8a6248f8ab1bf07844b9f97a
13 N994d8b4c7021437db73b519d2fb5738f
14 Na044d0f0b7634cde84352e4eae07f547
15 Nc44f4b324ba341118cef334b318579b7
16 Nc48cbb1a840e4c2295b9365d84a7e2f8
17 Ncb35e8b25d6b487195bd6c24dc39ac0f
18 Ndb076378770745f394e9949fd9270773
19 Nedeae2ee57434bdfb79813f1cf74c8bc
20 Nf506d6fb5bf14402be2b59bd01642424
21 Nf5b66f8a659644759753dccdef59bdb4
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author Nb148e5fd180e4d78b651d30a61194b4a
25 schema:citation sg:pub.10.1007/s00280-003-0585-0
26 sg:pub.10.1007/s10147-004-0407-3
27 schema:datePublished 2010-04
28 schema:datePublishedReg 2010-04-01
29 schema:description Background: Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial.Objective: To (i) identify the optimal regimen for IFL therapy in terms of irinotecan dosage, and (ii) determine the maximum tolerated dose and efficacy of the modified-IFL regimen in patients with histologically confirmed advanced colorectal cancer.Methods: In a phase I study, nine patients with advanced colorectal cancer received IFL treatment modified such that irinotecan was administered every 2 weeks, as opposed to the more toxic once-weekly administration. The study evaluated three escalating dose levels of irinotecan (100,125 and 150 mg/m2). Each treatment cycle consisted of irinotecan on days 1 and 15; fluorouracil 600 mg/m2 on days 1,8, 15 and 22; and levoleucovorin 250 mg/m2 on days 1, 8, 15 and 22. Data from the phase I study were used to determine the recommended dose of irinotecan for the phase II study. The latter study evaluated the effectiveness (overall response rate, median time to disease progression and median survival time) and tolerability of this modified-IFL therapy as ambulatory treatment in 22 patients with advanced colorectal cancer.Results: The dose-limiting toxicity of irinotecan was grade 3 neutropenia, which occurred in three patients at dose level 2 (125 mg/m2); furthermore, a fourth patient developed grade 4 neutropenia at this dose level. Therefore, 125 mg/m2 was considered to be the maximum tolerated dose, and the dose of irinotecan for the phase II study was set at 100 mg/m2. Fourteen patients achieved partial response using this modified-IFL regimen, and the overall response rate was 63.6% (95% CI 43.5, 83.7). The median time to progression was 197 days (range 111–283 days) and the median survival time was 414 days (95% CI 116, 712). Toxicities were acceptable and manageable.Conclusions: Modified-IFL therapy is a practical, effective and tolerable option for ambulatory treatment of advanced colorectal cancer.
30 schema:genre article
31 schema:isAccessibleForFree false
32 schema:isPartOf N30c437855957491298f29e43797588b3
33 N39755172be2f4d94a8fe0edab67beee3
34 sg:journal.1100199
35 schema:keywords IFL regimen
36 IFL therapy
37 IFL treatment
38 II study
39 administration
40 advanced colorectal cancer
41 ambulatory treatment
42 cancer
43 colorectal cancer
44 combined therapy
45 cycle
46 data
47 day 1
48 days
49 dosage
50 dose
51 dose level 2
52 dose levels
53 dose of irinotecan
54 dose-limiting toxicity
55 effectiveness
56 efficacy
57 fluorouracil
58 fourth patient
59 grade 3 neutropenia
60 grade 4 neutropenia
61 irinotecan
62 irinotecan dosage
63 latter study
64 level 2
65 levels
66 levoleucovorin
67 m2
68 maximum
69 median survival time
70 median time
71 metastatic colorectal cancer
72 neutropenia
73 optimal regimen
74 options
75 overall response rate
76 partial response
77 patients
78 phase I
79 phase II study
80 position
81 progression
82 rate
83 regimen
84 response
85 response rate
86 standard regimen
87 study
88 survival time
89 terms
90 therapy
91 time
92 tolerability
93 tolerable option
94 toxicity
95 treatment
96 treatment cycles
97 weekly administration
98 weeks
99 schema:name Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer
100 schema:pagination 243-249
101 schema:productId N2f1f61e083d64824964d8ddec88598b2
102 N3614dbd198494118b40c2722f06c35b9
103 Ne0557196951d442abe2482b1d5c562ae
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048774064
105 https://doi.org/10.2165/11534470-000000000-00000
106 schema:sdDatePublished 2022-09-02T15:54
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher N1551e7083f0a4eb593572cafb53586c2
109 schema:url https://doi.org/10.2165/11534470-000000000-00000
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N0b08eb48509a4d89a0a3f9fa65a391f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Adolescent
115 rdf:type schema:DefinedTerm
116 N1551e7083f0a4eb593572cafb53586c2 schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 N156d34aa33354cf28c235cfe654e9f77 rdf:first sg:person.01012215233.70
119 rdf:rest Ne02ad1494ae04f988e8db1ef5bd2baa3
120 N15af61532dd34f4398509678bdb36ed4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Antineoplastic Combined Chemotherapy Protocols
122 rdf:type schema:DefinedTerm
123 N15fd1b4dfea94c9c8d1cd6058642ca87 rdf:first sg:person.011653372052.41
124 rdf:rest Nee9fbd6fb277443ba639eee576795847
125 N1fff0c0f40a341bd9fee9206e14b73fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Aged
127 rdf:type schema:DefinedTerm
128 N22ae5899f740418d8a1176729a393cf9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Disease Progression
130 rdf:type schema:DefinedTerm
131 N2f1f61e083d64824964d8ddec88598b2 schema:name dimensions_id
132 schema:value pub.1048774064
133 rdf:type schema:PropertyValue
134 N30c437855957491298f29e43797588b3 schema:issueNumber 4
135 rdf:type schema:PublicationIssue
136 N3614dbd198494118b40c2722f06c35b9 schema:name pubmed_id
137 schema:value 20225907
138 rdf:type schema:PropertyValue
139 N378e8f7a732543e3a25e040d34b4d888 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Humans
141 rdf:type schema:DefinedTerm
142 N39755172be2f4d94a8fe0edab67beee3 schema:volumeNumber 30
143 rdf:type schema:PublicationVolume
144 N46c7216e5eb349f4bacd75317ec6ea8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Ambulatory Care
146 rdf:type schema:DefinedTerm
147 N4ce435b240d543c58167ab063bc466f7 rdf:first sg:person.01112102072.19
148 rdf:rest N75102f96aa3b44308e4d254dcbb0d60b
149 N5100114a722b40bf91ac043d31800ca7 rdf:first sg:person.01360270073.03
150 rdf:rest Nad1602eab49847ecaa59835a86b54235
151 N5a69455595dc46e385410333b5deb080 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Leucovorin
153 rdf:type schema:DefinedTerm
154 N620ae9c4978542e8b03ac960bb2bbc96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Survival Rate
156 rdf:type schema:DefinedTerm
157 N644a6aafdb6c4fc49790c3b18791a9f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Maximum Tolerated Dose
159 rdf:type schema:DefinedTerm
160 N72d960427b44453c8a2d06d956365a81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Treatment Outcome
162 rdf:type schema:DefinedTerm
163 N75102f96aa3b44308e4d254dcbb0d60b rdf:first sg:person.01253074264.90
164 rdf:rest Nb8f919b8f8cf4111bdd2310b4dc4f4eb
165 N76626651d94643b1bc61db4415f1d909 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Middle Aged
167 rdf:type schema:DefinedTerm
168 N76e0d04a8a6248f8ab1bf07844b9f97a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Dose-Response Relationship, Drug
170 rdf:type schema:DefinedTerm
171 N797a05648ddf4ce38201107b818ffcb7 rdf:first Na273d8b374d7454ca00be582ac2ab957
172 rdf:rest N4ce435b240d543c58167ab063bc466f7
173 N8fc0a41ebc624458b27af663ea89fe62 rdf:first sg:person.015540620202.97
174 rdf:rest N156d34aa33354cf28c235cfe654e9f77
175 N994d8b4c7021437db73b519d2fb5738f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Colorectal Neoplasms
177 rdf:type schema:DefinedTerm
178 Na044d0f0b7634cde84352e4eae07f547 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Fluorouracil
180 rdf:type schema:DefinedTerm
181 Na273d8b374d7454ca00be582ac2ab957 schema:affiliation grid-institutes:grid.39158.36
182 schema:familyName Watanabe
183 schema:givenName Masao
184 rdf:type schema:Person
185 Nad1602eab49847ecaa59835a86b54235 rdf:first sg:person.01157021235.19
186 rdf:rest N8fc0a41ebc624458b27af663ea89fe62
187 Nb148e5fd180e4d78b651d30a61194b4a rdf:first sg:person.01353257533.62
188 rdf:rest N5100114a722b40bf91ac043d31800ca7
189 Nb8f919b8f8cf4111bdd2310b4dc4f4eb rdf:first sg:person.01136563775.99
190 rdf:rest N15fd1b4dfea94c9c8d1cd6058642ca87
191 Nc44f4b324ba341118cef334b318579b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Young Adult
193 rdf:type schema:DefinedTerm
194 Nc48cbb1a840e4c2295b9365d84a7e2f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Camptothecin
196 rdf:type schema:DefinedTerm
197 Ncb35e8b25d6b487195bd6c24dc39ac0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Male
199 rdf:type schema:DefinedTerm
200 Ndb076378770745f394e9949fd9270773 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Drug Administration Schedule
202 rdf:type schema:DefinedTerm
203 Ne02ad1494ae04f988e8db1ef5bd2baa3 rdf:first sg:person.01226775545.80
204 rdf:rest N797a05648ddf4ce38201107b818ffcb7
205 Ne0557196951d442abe2482b1d5c562ae schema:name doi
206 schema:value 10.2165/11534470-000000000-00000
207 rdf:type schema:PropertyValue
208 Nedeae2ee57434bdfb79813f1cf74c8bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Adult
210 rdf:type schema:DefinedTerm
211 Nee9fbd6fb277443ba639eee576795847 rdf:first sg:person.0713475270.64
212 rdf:rest rdf:nil
213 Nf506d6fb5bf14402be2b59bd01642424 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Female
215 rdf:type schema:DefinedTerm
216 Nf5b66f8a659644759753dccdef59bdb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Neoplasm Metastasis
218 rdf:type schema:DefinedTerm
219 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
220 schema:name Medical and Health Sciences
221 rdf:type schema:DefinedTerm
222 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
223 schema:name Oncology and Carcinogenesis
224 rdf:type schema:DefinedTerm
225 sg:journal.1100199 schema:issn 1173-2563
226 1179-1918
227 schema:name Clinical Drug Investigation
228 schema:publisher Springer Nature
229 rdf:type schema:Periodical
230 sg:person.01012215233.70 schema:affiliation grid-institutes:grid.39158.36
231 schema:familyName Miyagishima
232 schema:givenName Takuto
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012215233.70
234 rdf:type schema:Person
235 sg:person.01112102072.19 schema:affiliation grid-institutes:grid.39158.36
236 schema:familyName Tateyama
237 schema:givenName Miki
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112102072.19
239 rdf:type schema:Person
240 sg:person.01136563775.99 schema:affiliation grid-institutes:grid.39158.36
241 schema:familyName Wakahama
242 schema:givenName Osamu
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136563775.99
244 rdf:type schema:Person
245 sg:person.01157021235.19 schema:affiliation grid-institutes:grid.39158.36
246 schema:familyName Fuse
247 schema:givenName Nozomu
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157021235.19
249 rdf:type schema:Person
250 sg:person.011653372052.41 schema:affiliation grid-institutes:grid.459767.e
251 schema:familyName Sakata
252 schema:givenName Yu
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011653372052.41
254 rdf:type schema:Person
255 sg:person.01226775545.80 schema:affiliation grid-institutes:grid.39158.36
256 schema:familyName Kudo
257 schema:givenName Mineo
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226775545.80
259 rdf:type schema:Person
260 sg:person.01253074264.90 schema:affiliation grid-institutes:grid.39158.36
261 schema:familyName Kunieda
262 schema:givenName Yasuyuki
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253074264.90
264 rdf:type schema:Person
265 sg:person.01353257533.62 schema:affiliation grid-institutes:grid.39158.36
266 schema:familyName Yuuki
267 schema:givenName Satoshi
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353257533.62
269 rdf:type schema:Person
270 sg:person.01360270073.03 schema:affiliation grid-institutes:grid.412167.7
271 schema:familyName Komatsu
272 schema:givenName Yoshito
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360270073.03
274 rdf:type schema:Person
275 sg:person.015540620202.97 schema:affiliation grid-institutes:grid.39158.36
276 schema:familyName Kato
277 schema:givenName Takashi
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015540620202.97
279 rdf:type schema:Person
280 sg:person.0713475270.64 schema:affiliation grid-institutes:grid.39158.36
281 schema:familyName Asaka
282 schema:givenName Masahiro
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713475270.64
284 rdf:type schema:Person
285 sg:pub.10.1007/s00280-003-0585-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075267208
286 https://doi.org/10.1007/s00280-003-0585-0
287 rdf:type schema:CreativeWork
288 sg:pub.10.1007/s10147-004-0407-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037532393
289 https://doi.org/10.1007/s10147-004-0407-3
290 rdf:type schema:CreativeWork
291 grid-institutes:grid.39158.36 schema:alternateName Department of Gastroenterology, Hokkaido University, Sapporo, Japan
292 schema:name Department of Gastroenterology, Hokkaido University, Sapporo, Japan
293 rdf:type schema:Organization
294 grid-institutes:grid.412167.7 schema:alternateName Department of Cancer Chemotherapy Division, Hokkaido University Hospital Cancer Center, Nishi-5, Kita-14, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan
295 schema:name Department of Cancer Chemotherapy Division, Hokkaido University Hospital Cancer Center, Nishi-5, Kita-14, Kita-ku, Sapporo, 060-8638, Hokkaido, Japan
296 rdf:type schema:Organization
297 grid-institutes:grid.459767.e schema:alternateName Department of Gastroenterology, Misawa City Hospital, Misawa, Japan
298 schema:name Department of Gastroenterology, Misawa City Hospital, Misawa, Japan
299 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...